not known, an increasing body of evidence suggests that the virally encoded chemokine receptor or G protein-coupled receptor (vGPCR), the product of ORF74, plays an important role. It activates multiple signaling pathways and transcription factors in the absence of added ligands (3, 12, 30, 32-34, 39, 41, 42) , resulting in the induction of synthesis of various proinflammatory cytokines, growth factors, and cell surface adhesion proteins. More strikingly, mice transgenic (Tg) for vGPCR develop lesions that closely resemble KS (25, 26, 46) .
The vGPCR clearly does not function as a classic oncogene. It is expressed during the lytic phase of viral gene expression (11, 25, 26, 35, 38, 46) , and cells expressing it likely die. However, factors released by these cells could influence the behavior of surrounding cells that are not expressing vGPCR; indeed, factors released by cells expressing vGPCR elicit chemotaxis of T lymphoid and monocytic cells and induce NF-B activation in cells not expressing vGPCR (33) . Consistent with this, tumors of vGPCR Tg mice express detectable transgene product in only a minority of cells in the tumor (25, 46) . Indeed, mice with a vGPCR transgene regulated by a CD2 promoter express the transgene only in T cells that infiltrate the tumor and not in the endothelial spindle cells that make up the bulk of the tumor and are thought to be the abnormal cells in KS (46) .
Recently, it has been shown that Tat synergistically increases the levels of NF-AT and NF-B activation by vGPCR (34, 46) , suggesting a possible pathogenic mechanism for Tat in KS. We have derived a cell line from a KS-like tumor of a vGPCR Tg mouse that causes tumors when transplanted into nude mice (25) . Here we show that Tat accelerates tumorigenesis by this KS tumor-derived cell line.
MATERIALS AND METHODS
Mice. The generation of vGPCR Tg mice has been described previously (25) . Briefly, a plasmid expressing the HHV-8 vGPCR under the regulation of an early simian virus 40 promoter was microinjected into fertilized one-cell C57BL/6J eggs, and the resultant eggs were transplanted into a pseudopregnant female. A Tg line was developed from the offspring in which approximately 30% of the mice develop KS-like lesions by 1 year of age. Tumor induction studies were performed with a cell line developed from one of the tumors and CR:NIH-BgNu-XID immunodeficient mice.
Cells and plasmids. The GR3 cell line was developed by two serial passages through nude mice of cells from a KS-like tumor of a vGPCR Tg mouse. GR3 cells express vGPCR and cause tumors in 100% of nude mice and with lesser efficiency in immunocompetent mice. The GR5 cell line was derived from the tail tissue of a non-Tg littermate by explantation as previously described (25) and is not tumorigenic in nude mice. A plasmid containing a codon-optimized synthetic open reading frame encoding the full-length Tat of HIV-1(MN) has been described previously (1) . A codon-optimized deletion mutant of Tat, Tat⌬30-51, was also synthesized and has been previously described (1) . Tat⌬30-51 lacks the cysteine-rich region of Tat and is defective for transactivation of the HIV-1 long terminal repeat. Plasmids were transfected into GR3 and GR5 cells by the Ca 3 (PO 4 ) 2 method.
Signal transduction assays and Western blot analyses. The activation of the transcription factors NF-B and NF-AT was assayed by DNA binding assays by using nuclear extracts prepared from transfected cells or tumor tissues. Binding assays were performed on nuclear extracts by using oligonucleotides containing NF-B or NF-AT consensus binding sites and TransAM enzyme-linked immunosorbent assay (ELISA)-based kits from Active Motif (Carlsbad, Calif.) under conditions recommended by the manufacturer. Binding by the appropriate antibody was detected with a horseradish peroxidase-coupled second antibody, and absorbance at 450 nm was determined. In some cases, the activation levels of NF-B and NF-AT were measured by cotransfection with a luciferase gene HIV-1 Tat ACCELERATES TURMORIGENESIS 9337 driven by a basal promoter containing multiple consensus binding sites for the appropriate factor under conditions specified by the manufacturer (PathDetect; Stratagene, La Jolla, Calif.). Western blotting for vGPCR was performed by using a previously described antibody against a synthetic peptide based on the vGPCR sequence (11) . The phosphorylation of Akt and selected substrates of Akt was analyzed by Western blotting by using phospho-specific antibodies and by reprobing the blots with antibodies to several of the appropriate total proteins and comparing the signals. Antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif.) or Cell Signaling Technology (Beverly, Mass.).
Tumor induction studies. For tumorigenesis studies, GR3 cells (generally, 0.5 ϫ 10 6 cells except where otherwise noted) were injected intramuscularly into the flanks of nude mice. Transfected cells were injected 72 h following transfection. Tumor formation was followed by visual inspection every 2 to 3 days. When tumors were visible, they were measured in two dimensions. When animals were euthanized, tumors were excised, weighed, and sectioned for histology, immunohistochemistry, and signal transduction assays.
RT-PCR. Reverse transcription-PCR (RT-PCR) and real-time RT-PCR for vGPCR, vascular endothelial growth factor A (VEGF-A) and VEGF-C mRNA, and 18S rRNA were performed as described previously (25) . Real-time RT-PCR for macrophage inflammatory protein 2 (MIP-2) was performed by using 5Ј-CC ACCAACCACCAGGCTACA-3Ј and 5Ј-GCGAGGCACATCAGGTACGA-3Ј as the sense and antisense primers, respectively, to generate a 351-bp product.
RESULTS
Tumor formation by vGPCR Tg GR3 tumor cells. It was previously reported that approximately 30% of mice with a transgene encoding the HHV-8 vGPCR develop KS-like tumors (25) . When injected into mice, a cell line developed from a tumor of one of the F 2 generation of Tg mice caused tumors within 3 weeks in 100% of nude mice and in one of four immunocompetent mice. In contrast, cells derived from normal tail tissue of a non-Tg littermate did not cause tumors in any of 10 nude mice. Cells from one of the nude mouse tumors were cultured and injected into nude mice and again gave tumors in all recipients within 3 weeks, and cells cultured from these tumors retained their tumorigenic potential. Figure 1A shows a typical tumor. A cell line (GR3) developed from one of these tumors was used for subsequent studies.
The GR3 cell line expresses vGPCR RNA and protein, as determined by RT-PCR, immunohistochemistry, and Western blotting. The GR3 cell line also expresses high levels of mRNA for VEGF-C, but not VEGF-A, compared to levels in cells cultured from normal mouse tail tissue, as determined by realtime RT-PCR (Fig. 1B) . However, the expression of VEGF-C RNA does not appear to be directly induced by vGPCR, as judged by transfection of vGPCR into NIH 3T3 cells (data not shown).
Enhancement of NF-B and NF-AT activation by Tat. It has previously been shown that HIV-1 Tat protein, either provided as an extracellular protein or encoded by transfected DNA, synergistically increases the activation of NF-B and NF-AT by vGPCR (34) . We wondered whether Tat would also increase levels of NF-B and NF-AT activation in the GR3 tumor cell line, which constitutively expresses vGPCR. GR3 cells were transfected with either a Tat expression plasmid or an empty control vector, and nuclear extracts were prepared from the transfected cells. Transfected Tat increased the levels of activation of both NF-B ( Fig. 2A) and NF-AT (Fig. 2B ) in GR3 cells two-to threefold, similar to its effects in normal cells transiently expressing vGPCR. Tat alone had little effect on NF-B and NF-AT signaling. Transfection of a Tat expression construct into GR5 cells did not greatly increase the activation level of either factor unless an expression construct for vGPCR was cotransfected (Fig. 3) . The expression levels of vGPCR protein were similar in GR3 cells with and without transfected Tat (Fig. 4A) , indicating that the signal increases are not due to upregulation of vGPCR expression.
Tat synergistically increases NF-B and NF-AT activation by vGPCR in human cells through the phosphatidylinositol 3-kinase (PI3-K)/Akt/protein kinase B pathway (34) . We asked whether Tat would have a similar effect on the PI3-K/Akt pathway in GR3 cells. We therefore measured the phosphorylation levels of Akt as well as that of BAD and glycogen synthetase kinase 3␤ (GSK-3␤), two of the downstream targets of Akt phosphorylation. Phosphorylation of both Akt (Fig. 4B ) and its downstream targets (Fig. 4C and D) was clearly increased by Tat, while the levels of total protein remained constant. Figure 4E shows the quantification of the results by PhosphorImager analysis of selected bands, expressed in arbitrary pixel units. Thus, it is likely that Tat is acting by similar mechanisms on vGPCR signaling in GR3 cells and vGPCRtransfected human cells.
The murine chemokine MIP-2, a homologue of human Gro␣, is an agonist for vGPCR (26) , and vGPCR mutants that retain constitutive signal transduction but fail to respond to MIP-2 are not highly tumorigenic when expressed as transgenes (26). Since MIP-2 is regulated in part by NF-B (45), we asked whether Tat increased the level of MIP-2 mRNA expression in GR3 cells. As judged by real-time RT-PCR, this was indeed the case. In numerous experiments upregulation at 24 and 48 h posttransfection ranged from approximately twofold (data not shown) to eightfold (Fig. 5) . ELISAs of media collected 48 h posttransfection showed an approximately 50% increase in secreted MIP-2 (data not shown). Neither VEGF-A nor VEGF-C mRNA levels were affected by Tat, although VEGF-C is already upregulated in GR3 cells (Fig. 1B) . Enhancement of tumorigenesis by Tat. Since Tat increased NF-B and NF-AT activation levels in GR3 cells, an obvious question was whether Tat would also increase or accelerate tumorigenesis by GR3 cells. GR3 cells were transfected with an expression construct for Tat or a control plasmid (pSG5) as described in Materials and Methods. Cells were cultured for 72 h and then injected into groups of five nude mice for each construct. Mice were observed every 2 to 3 days for the ap- pearance of tumors at the site of injection, and the tumors were measured in two dimensions after they first became visible. As shown in Fig. 6A , tumors in two of the mice receiving cells transfected with Tat were detectable by day 9 postinoculation. The earliest appearance of a tumor in the control group was at day 11, by which time four out of five mice from the Tat group had detectable tumors. As judged from the surface area of the tumor, the tumor growth rate was strikingly higher with the Tat group compared to the rate for the controls. The data are summarized in Fig. 6B . Tumors were removed at day 16 and sectioned for further analysis, including weight measurement. Only one of the four tumors in mice injected with GR3 cells transfected with the control vector was large enough to excise clearly; it weighed 0.36 g. The five tumors in the Tat group had an average weight of 0.6 Ϯ 0.2 g. Nuclear extracts were prepared from tumor slices, and the levels of activation of NF-B and NF-AT were measured by using ELISA-based DNA binding assays. Activation levels of both factors were slightly but reproducibly higher in tumors containing the Tat-transfected cells (Fig. 2C and D) . The relatively small differences between cells treated with Tat and the control vector may reflect a gradual decrease in the expression level of the transiently transfected Tat. Indeed, although we could readily detect by Western blotting Tat expression in recently transfected cells (Fig. 4) , we could not detect Tat expression in the tumors (data not shown). Thus, it is likely that the effects of Tat occur relatively early in tumor formation.
Although HIV-1 and HHV-8 do not generally infect the same cells, cells infected with each virus likely exist in close proximity. Therefore, Tat and vGPCR would mostly be expressed in different cells, although Tat can be released from HIV-1-infected cells and enter or bind to HHV-8-infected cells. To model this relationship, we transfected normal GR5 cells with a Tat expression vector or a control vector, mixed them with GR3 cells, and injected the mixture into nude mice. We again observed the mice every 2 to 3 days and determined the time of appearance of tumors. As shown in Fig. 7A , when the GR5 normal cells were transfected with the Tat plasmid, tumors appeared more rapidly than when the GR5 cells were transfected with the control vector. We also carried out a series of experiments in which the two cell types were not mixed but were injected on opposite sides of nude mice. Interestingly, under these conditions Tat again accelerated tumor formation, indicating that the effects of Tat on tumorigenesis can occur at a distance (Fig. 7B) . In no instance did we observe tumors on the sides of mice that were injected with Tat-transfected GR5 cells, suggesting that Tat itself is not tumorigenic.
DISCUSSION
We and others have previously shown that the HHV-8 vGPCR activates multiple parallel signaling pathways, including NF-B, NF-AT, and AP-1, in the absence of added ligands (3, 8, 12, 30, (32) (33) (34) (39) (40) (41) (42) . NF-B and NF-AT signaling by vGPCR are synergistically increased by HIV-1 Tat protein (34) . The effects of both vGPCR and Tat on signaling are dependent on the PI3-K/Akt pathway. In this regard, Tat has been shown to prevent down-regulation of Akt in vincristinetreated KS cells (14) . The expression of vGPCR from a transgene or from a transfected expression vector causes the formation of KS-like tumors in mice (4, 25, 26, 46) . The transduction of endothelial cells with a vGPCR retroviral vector also induces KS-like lesions in mice (29) .
In the present studies we evaluated whether Tat can increase vGPCR-mediated tumorigenesis. For this purpose, we used GR3, a cell line derived from a KS-like tumor of a vGPCR Tg mouse and passaged several times as a tumor through nude mice. GR3 cells constitutively express vGPCR and elevated levels of VEGF-C mRNA and form tumors when injected into nude mice. We have looked for stimulation of tumorigenesis by Tat in this model system by two criteria, tumor size as measured by weight or surface area and the time until appearance of discernible tumors. By both criteria, transfection of a Tat expression vector into the tumor cells greatly increased tumorigenesis. Activation of NF-B and NF-AT in the GR3 cells was increased by the transfection of Tat, consistent with previous results in human cells (34) . Tat did not increase the level of expression of vGPCR, suggesting that its primary effect on tumorigenesis is to increase the strength of vGPCR signaling.
Although these data suggest that Tat could contribute to KS pathogenesis by cooperating with vGPCR, infection of the same cells by the two viruses is likely to be infrequent. Hence, expression of both proteins in the same cell is not likely. However, Tat is released by HIV-1 infected cells and can be taken up by other cells (9, 16, 19) . We therefore sought to more closely mimic the in vivo situation by expressing Tat and vGPCR in separate cells and looking for a paracrine effect on tumorigenesis. We transfected the Tat expression vector into normal mouse tail GR5 cells and either mixed them with GR3 tumor cells and injected them together into nude mice or injected the Tat-transfected and tumor cells separately into opposite sides of nude mice. In both cases, the results were similar to those obtained with Tat-transfected tumor cells. The formation of tumors was clearly enhanced, indicating that Tat and vGPCR need not be expressed in the same cell in order for Tat to cooperate in vGPCR-mediated tumorigenesis and that effects from Tat may occur at a distance.
The precise mechanism by which Tat increases vGPCRmediated signaling is not clear. Interestingly, however, expression of Tat in GR3 cells increased the level of expression of MIP-2, the murine homologue of Gro␣. HHV-8 infection induces the expression of Gro␣ from human endothelial cells (27) . Both Gro␣ and MIP-2 are agonists for vGPCR, and the interaction of MIP-2 and vGPCR appears to be important for tumorigenesis in Tg mice (26) . Tat may therefore upregulate the activities of vGPCR through its induction of Gro␣, although this then begs the question of how Tat induces Gro␣.
The data indicate that Tat may indeed play a role in KS pathogenesis by increasing vGPCR-mediated signaling in people dually infected with HIV-1 and HHV-8, although the degree to which this interaction plays a role is not clear. Tat concentrations of up to 1 ng/ml in serum have been reported (43) . Since Tat is readily taken up by cells or bound on their surfaces, however, it would probably act locally, and local concentrations are likely to be considerably higher than the concentration in serum. It is also possible, however, that the enhancement of tumorigenesis is not mediated by extracellular Tat but, rather, by cytokines or other soluble factors induced from cells expressing Tat. In either case, the present data provide a potential mechanism by which HIV-1 could contribute to KS pathogenesis by HHV-8.
